Navigation Links
How chemo kills tumors: research to reduce side effects
Date:8/6/2008

er Cell (August 2008), have shown how different tumours respond to the anti-mitotic drugs which target the mitotic spindle (the structure that separates the chromosomes during cell division) and revealed that the variation in cell behaviour was far greater than previously recognized.

They used a high throughput automated time-lapse light microscopy approach to systematically analyze over 10,000 single cells from 15 cell lines in response to three different classes of anti-mitotic drug. This revealed the large variation in cell behavior with cells within any given line exhibiting multiple fates.

Dr Taylor explained: "We know that anti-mitotic drugs block the final stage of the cell division process, mitosis. How the cells then die is a mystery.

"We embarked on a fresh, more direct approach that is actually quite simple. Basically, we just watched the cells using time-lapse microscopy; this allowed us to track the behaviour of individual cells and determine their fate when exposed to different anti-mitotic drugs.

"The first thing we realised was that the picture was much more complicated that we originally thought; the range of different behaviours was profound. Not only did cells from different cell lines behave differently, but cells within the same line also behaved differently.

"The level of complexity was at first overwhelming. However, as we slowly made our way through the data, patterns began to emerge. This allowed us to formulate a new hypothesis. We were then able to design more experiments to test this hypothesis.

"In essence, it turns out that when cells are exposed to these drugs they arrest in mitosis. Then a race starts between two competing cellular signalling networks. One network is trying to kill the cell, the other is trying to cause the cell to exit mitosis and thus allow the cell to survive. The winner of the race decides the fate of the cell; death or survival.

"The factors inf
'/>"/>

Contact: Mikaela Sitford
Mikaela.Sitford@manchester.ac.uk
01-612-752-111
University of Manchester
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. TG2 identified as potential therapeutic target in chemo-resistant ovarian cancer
2. Mitochondrial cholesterol makes response to chemotherapy difficult in hepatic cancer
3. Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer
4. New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
5. Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors
6. A search for protection against chemotherapy cardiotoxicity
7. UC health news: molecular pathway may predict chemotherapy effectiveness
8. Food scientists confirm commercial product effectively kills bacteria in vegetable washwater
9. New UGA invention effectively kills foodborne pathogens in minutes
10. Mounting evidence shows red wine antioxidant kills cancer
11. New decontamination system kills anthrax rapidly without lingering effects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)...   Zynx Health ™, the market leader ... today announced that its ZynxCarebook ™ mobile ... smartphones and tablets. With this expansion, care team ... ZynxCarebook to securely exchange messages and share assessments ... to other care settings, and improve clinical outcomes ...
(Date:7/21/2015)... Passwords have proven futile for securing ... U.S. Office of Personnel Management breach. Biometric authentication ... but developers and end-users are concerned about how ... Biometrics-as-a-Service provider HYPR Corp. announced today the general ... party integration. A video overview ...
(Date:7/9/2015)... , July 07, 2015 ... announced the addition of the "Biometrics for ... Forecasts 2015-2020" report to their offering. ... major contributor to this growth and the forecast ... billion in revenue for companies involved in delivering ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... the genetics of so many organisms that have different ... gathering full sets of genetic information from organisms rapidly ... to the "trees" of each individual case and detail. ... Science by David Wake, Marvalee Wake and Chelsea ...
... Mouse models are yielding important clues about the nature ... in 110 children in the U.S.[1] In labs at ... studying strains of mice that inherently mimic the repetitive ... Georgianna Gould, Ph.D., research assistant professor of physiology in ...
... ESCEO will be staging the European Congress on ... in Europe, to be held in Valencia, Spain ... of March 7, 2011 fast approaches, registrants are ... 1st IOF-ESCEO Pre-Clinical Symposium (from March 22-23, 2011). ...
Cached Biology News:Serotonin plays role in many autism cases, studies confirm 28 special sessions at European Congress on Osteoporosis and Osteoarthritis in Valencia 2
(Date:7/30/2015)... , July 30, 2015 Ascendis ... company that applies its innovative TransCon technology to ... top-line results from a six-month Phase 2 study ... TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal children ... "We are extremely pleased with the top-line results ...
(Date:7/30/2015)... , July 30, 2015  Discovery Laboratories, ... it has received the second $1.0M tranche under ... Research (SBIR) grant valued at up to $3.0 ... aerosolized KL4 surfactant as a potential medical countermeasure ...  Discovery Labs was awarded an initial $1.0 million ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's ... designed for continuous operation up to 1500 bar. The sanitary design gauge of ... preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal solution for ...
(Date:7/29/2015)... -- Sanofi, un leader mondial et ... le premier semestre 2015. Le Directeur Général ... Visionner l,interview vidéo et lire la transcription :  ... sommaire de l,interview :  - Résultats ... - Diabète - Praluent ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... implementation of quality systems in product design ... ... assay, COLUMBIA, Md., Oct. 1 Cylex has ... 13485:2003 certification,includes compliance with the Canadian Medical Devices Conformity ...
... Sept. 30 Synthetech, Inc. (OTC,Bulletin Board: NZYM) ... Director of Manufacturing effective on October 1, 2008. ... to Synthetech. Dr. Farkas,has over 13 years, experience ... previous positions in manufacturing and supply chain,management at ...
... Presidential Support for Faster Registration ... of Modern Medicines in Ukraine -, ... of MaxWell Biocorporation, LLC, and Dr. Peter M. Leitner, President ... honor,Ukrainian President Victor Yushchenko., (Logo: http://www.newscom.com/cgi-bin/prnh/20080624/NETU078LOGO ), ...
Cached Biology Technology:Cylex(TM) Receives ISO 13485:2003 and 9001:2000 Quality Certifications 2Synthetech Announces New Director of Manufacturing 2Ukrainian President Yushchenko: Pharmaceuticals 'Very Important' 2
... DTT White solid.. PACKAGED UNDER INERT ... so reaction is "driven" to completion. A protective ... surfactant found in many other preparations. Blocks the ... ≥97% by titration. Contaminants: Heavy metals: ...
... virus of Japan, also named Sendai virus) ... transfection of molecules by means of membrane ... (RNAi), Protein, Oligo, cDNA, Antibodies, Vector, and ... GenomONE-Neo EX has a high fusing capability ...
... Whole Genome ChIP-on-chip Microarray is specifically ... (S. cerevisiae) DNA binding proteins by ... DNA microarrays. This set delivers robust ... greater true binding events and fewer ...
... highest precision, more user-friendliness and absolute reliability ... the definition of the Mastercycler ep system. ... research has been developing dynamically. The same ... Systems. To keep pace with these ...
Biology Products: